Elranatamab Active in Relapsed or Refractory Multiple Myeloma

(MedPage Today) -- Data presented at the 2022 American Society of Hematology (ASH) annual meeting showed that elranatamab induces responses in relapsed or refractory multiple myeloma, and has a manageable safety profile.
In this exclusive MedPage...